Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D3AI
|
||||
| Former ID |
DCL000150
|
||||
| Drug Name |
L-NAME
|
||||
| Synonyms |
N-Nitroarginine methyl ester; NG-NITROARGININE METHYL ESTER; N(G)-Nitroarginine methyl ester; N-Nitro-L-arginine methylester; Ngamma-Nitro-L-arginine methyl ester; N(G)-Nitro-L-arginine methyl ester; N(sup G)-Nitro-L-arginine methyl ester; N-omega-Nitro-O-arginine methyl ester; Methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate; Methyl N5-(N'-nitrocarbamimidoyl)-L-ornithinate; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester; N-.omega.-Nitro-O-arginine methyl ester; L-Ornithine, N(5)-(imino(nitroamino)methyl)-, methyl ester; Methyl (2S)-2-amino-5-[(amino-nitramido-methylidene)amino]pentanoate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Registry Operator
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C7H15N5O4
|
||||
| InChI |
InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1
|
||||
| InChIKey |
KCWZGJVSDFYRIX-YFKPBYRVSA-N
|
||||
| CAS Number |
CAS 50903-99-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6988, 799994, 11113631, 11120322, 11120810, 11121298, 11121786, 11122266, 11362975, 11365537, 11368099, 11371101, 11371102, 11373700, 11376261, 14717146, 14749398, 15121709, 15121710, 26751830, 26751831, 34705694, 47959523, 48034876, 48259010, 48259011, 49737752, 50104531, 50104532, 50104533, 56310758, 56311189, 56311968, 57312345, 59831004, 76083057, 87550947, 90340714, 92310137, 99301049, 99302569, 103166542, 103995882, 104332835, 119503169, 124750046, 128364160, 134338830, 135001289, 135654724
|
||||
| Target and Pathway | |||||
| Target(s) | Nitric-oxide synthase, endothelial | Target Info | Inhibitor | [535004], [537587], [537590] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| NetPath Pathway | Wnt Signaling Pathway | ||||
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
| Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
| Angiopoietin receptor Tie2-mediated signaling | |||||
| Thromboxane A2 receptor signaling | |||||
| SHP2 signaling | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| PAR1-mediated thrombin signaling events | |||||
| References | |||||
| Ref 468266 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5213). | ||||
| Ref 526685 | Inhibition of nitric oxide synthase by L-NAME speeds phase II pulmonary .VO2 kinetics in the transition to moderate-intensity exercise in man. J Physiol. 2003 Oct 1;552(Pt 1):265-72. Epub 2003 Aug 1. | ||||
| Ref 535004 | L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators Inflamm. 2000;9(1):25-30. | ||||
| Ref 537587 | Enhanced pulmonary expression of the TrkB neurotrophin receptor in hypoxic rats is associated with increased acetylcholine-induced airway contractility. Acta Physiol (Oxf). 2009 Jul 6. | ||||
| Ref 537590 | Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Jul 5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.